First Time Loading...

Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 26.33 EUR 0.34% Market Closed
Updated: Apr 20, 2024

Operating Margin
Bayer AG

17.7%
Current
4%
Average
7.6%
Industry
Positive for the last year
17.7%
Positive average
4%
Better than average
Better than industry value

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
17.7%
=
Operating Profit
8.4B
/
Revenue
47.6B

Operating Margin Across Competitors

Operating Margin Comparison
Bayer AG Competitors

Country Company Market Cap Operating
Margin
DE
Bayer AG
XETRA:BAYN
25.9B EUR
18%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
689.5B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK
45%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
356B USD
29%
US
Merck & Co Inc
NYSE:MRK
318.4B USD
7%
UK
AstraZeneca PLC
LSE:AZN
169.7B GBP
19%
CH
Roche Holding AG
SIX:ROG
176.3B CHF
33%
CH
Novartis AG
SIX:NOVN
174.4B CHF
27%
US
Pfizer Inc
NYSE:PFE
146.8B USD
22%
Bayer AG
XETRA:BAYN
Country DE
Market Cap 25.9B EUR
Operating Margin
18%
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Eli Lilly and Co
NYSE:LLY
Country US
Market Cap 689.5B USD
Operating Margin
30%
Novo Nordisk A/S
CSE:NOVO B
Country DK
Market Cap 3.9T DKK
Operating Margin
45%
Dechra Pharmaceuticals PLC
LSE:DPH
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Johnson & Johnson
NYSE:JNJ
Country US
Market Cap 356B USD
Operating Margin
29%
Merck & Co Inc
NYSE:MRK
Country US
Market Cap 318.4B USD
Operating Margin
7%
AstraZeneca PLC
LSE:AZN
Country UK
Market Cap 169.7B GBP
Operating Margin
19%
Roche Holding AG
SIX:ROG
Country CH
Market Cap 176.3B CHF
Operating Margin
33%
Novartis AG
SIX:NOVN
Country CH
Market Cap 174.4B CHF
Operating Margin
27%
Pfizer Inc
NYSE:PFE
Country US
Market Cap 146.8B USD
Operating Margin
22%

Profitability Report

View the profitability report to see the full profitability analysis for Bayer AG.

Full Profitability Report

See Also

Summary
BAYN intrinsic value, competitors valuation, and company profile.
DCF Valuation
BAYN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BAYN stock valuation using valuation multiples.
Wall Street Estimates
BAYN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BAYN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
17.7%
=
Operating Profit
8.4B
/
Revenue
47.6B
What is the Operating Margin of Bayer AG?

Based on Bayer AG's most recent financial statements, the company has Operating Margin of 17.7%.

ALPHA SPREAD
Join more than 129,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.